118 related articles for article (PubMed ID: 19915976)
1. Fifteen-year trends in metastatic breast cancer survival in Greece.
Dafni U; Grimani I; Xyrafas A; Eleftheraki AG; Fountzilas G
Breast Cancer Res Treat; 2010 Feb; 119(3):621-31. PubMed ID: 19915976
[TBL] [Abstract][Full Text] [Related]
2. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
[TBL] [Abstract][Full Text] [Related]
3. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
Gennari A; Conte P; Rosso R; Orlandini C; Bruzzi P
Cancer; 2005 Oct; 104(8):1742-50. PubMed ID: 16149088
[TBL] [Abstract][Full Text] [Related]
4. Ten years of experience with weekly chemotherapy in metastatic breast cancer patients: multivariate analysis of prognostic factors.
Nisticò C; Cuppone F; Bria E; Fornier M; Giannarelli D; Mottolese M; Novelli F; Natoli G; Cognetti F; Terzoli E
Anticancer Drugs; 2006 Nov; 17(10):1193-200. PubMed ID: 17075319
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005.
Geiger S; Cnossen JA; Horster S; DiGioia D; Heinemann V; Stemmler HJ
Anticancer Drugs; 2011 Oct; 22(9):933-9. PubMed ID: 21666437
[TBL] [Abstract][Full Text] [Related]
6. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for breast cancer.
Hennessy BT; Pusztai L
Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
9. [Current trends in pharmacotherapy of breast cancer].
Boér K
Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
[TBL] [Abstract][Full Text] [Related]
10. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era.
Sonneveld DJ; Hoekstra HJ; van der Graaf WT; Sluiter WJ; Mulder NH; Willemse PH; Koops HS; Sleijfer DT
Cancer; 2001 Apr; 91(7):1304-15. PubMed ID: 11283931
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy of metastatic breast cancer: the truth beyond the clinical trials.
Gueth U; Huang DJ; Schoetzau A; Holzgreve W; Wight E
Oncology; 2009; 76(4):247-53. PubMed ID: 19246949
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
15. Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first-line treatment: prognostic factors.
Brun B; Benchalal M; Lebas C; Piedbois P; Lin M; Lebourgeois JP
Cancer; 1997 Jun; 79(11):2137-46. PubMed ID: 9179060
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
[TBL] [Abstract][Full Text] [Related]
17. [Does primary tumor affect the prognosis in postmastectomy locoregional recurrence in breast carcinoma?].
Willner J; Kiricuta IC; Kölbl O
Strahlenther Onkol; 1995 Jan; 171(1):18-28. PubMed ID: 7839301
[TBL] [Abstract][Full Text] [Related]
18. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.
Roché H; Yelle L; Cognetti F; Mauriac L; Bunnell C; Sparano J; Kerbrat P; Delord JP; Vahdat L; Peck R; Lebwohl D; Ezzeddine R; Curé H
J Clin Oncol; 2007 Aug; 25(23):3415-20. PubMed ID: 17606972
[TBL] [Abstract][Full Text] [Related]
20. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]